9.2%
Revenue Growth
STE achieved a 9.2% year-over-year increase in revenue, driven by strong sales across key segments.
Source: Source: 10-Q Income Statement, p.1
AI Takeaway
STE reported strong financial performance in Q3 FY2026 with significant growth in revenue and net income, supported by improved operating efficiency and reduced long-term debt.
Revenue
$1.5B
++9.16% YoY
EPS (Basic)
$1.96
++11.36% YoY
Gross Margin
43.8%
-0.72% YoY
Operating Income
$273.2M
++11.37% YoY
Filed · Analysis updated · Source: SEC EDGAR 10-Q filing
STE achieved a 9.2% year-over-year increase in revenue, driven by strong sales across key segments.
Source: Source: 10-Q Income Statement, p.1
Despite a 10.6% increase in the cost of revenue, operating margins improved slightly due to effective cost management and operational efficiencies.
Source: Source: 10-Q Income Statement, p.1
Operating cash flow increased by 13.4% year-over-year, indicating strong cash generation capabilities.
Source: Source: 10-Q Cash Flow, p.1
Potential disruptions in the supply chain could impact production and delivery schedules, affecting revenue and profitability.
Source: Source: General Industry Risk Analysis
Unlock 2 more detailed risk analysis
Upgrade to unlockReported EPS of $2.53 versus the $2.56 analyst consensus — a -1.1% miss for Q3 FY2026.
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $1.5B | $1.37B | +9.16% |
Cost of Revenue | $840.7M | $760.2M | +10.59% |
Gross Profit | $655.5M | $610.3M | +7.41% |
Operating Income | $273.2M | $245.3M | +11.37% |
Net Income | $192.9M | $173.5M | +11.18% |
EPS (Basic) | $1.96 | $1.76 | +11.36% |
EPS (Diluted) | $1.96 | $1.75 | +12.00% |
R&D Expense | $29.5M | $27.4M | +7.66% |
SG&A Expense | $352.3M | $335.5M | +5.01% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $10.59B | $10.01B | +5.83% |
Current Assets | $2.29B | $1.9B | +20.46% |
Total Liabilities | $3.42B | $3.58B | -4.37% |
Current Liabilities | $922.3M | $891.12M | +3.50% |
Stockholders' Equity | $7.15B | $6.42B | +11.51% |
Cash & Equivalents | $423.7M | $155.18M | +173.04% |
Long-Term Debt | $1.9B | $2.04B | -6.88% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash FlowYTD | $1.01B | $887.3M | +13.38% |
Investing Cash FlowYTD | $-295.3M | $458.6M | -164.39% |
Financing Cash FlowYTD | $-470.3M | $-1.39B | +66.27% |
Share BuybacksYTD | $161.2M | $211.1M | -23.64% |
D&AYTD | $363.1M | $353.9M | +2.60% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Gross Margin | 43.8% | 44.5% | -0.72% |
Operating Margin | 18.3% | 17.9% | +0.36% |
Net Margin | 12.9% | — | — |
ROE | 2.7% | — | — |
ROA | 1.8% | — | — |
Current Ratio | $2.479 | — | — |
Debt to Equity | $0.479 | — | — |
Other companies in Health Care Equipment
The filing does not provide specific analyst estimates, but STE reported a strong performance with a 11.4% increase in EPS to $1.96.
Key takeaways include a 9.2% increase in revenue, a 11.2% rise in net income, and improved operating efficiency despite higher costs.
Key risks include supply chain disruptions, regulatory changes, and intense market competition.
STE's revenue grew by 9.2% year-over-year to $1.4962 billion, driven by strong sales performance.
STE's financial health appears strong with increased revenue, improved net income, and a significant rise in cash and equivalents by 173%.